INDV vs. BBIO, LEGN, ELAN, CYTK, NUVL, GRFS, AXSM, VKTX, TGTX, and KRYS
Should you be buying Indivior stock or one of its competitors? The main competitors of Indivior include BridgeBio Pharma (BBIO), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Grifols (GRFS), Axsome Therapeutics (AXSM), Viking Therapeutics (VKTX), TG Therapeutics (TGTX), and Krystal Biotech (KRYS). These companies are all part of the "pharmaceutical products" industry.
Indivior vs.
Indivior (NASDAQ:INDV) and BridgeBio Pharma (NASDAQ:BBIO) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, community ranking, institutional ownership, profitability, valuation, analyst recommendations and media sentiment.
Indivior currently has a consensus target price of $16.00, suggesting a potential upside of 30.83%. BridgeBio Pharma has a consensus target price of $48.08, suggesting a potential upside of 33.25%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Indivior.
BridgeBio Pharma received 160 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 71.19% of users gave BridgeBio Pharma an outperform vote.
Indivior has a net margin of -0.17% compared to BridgeBio Pharma's net margin of -201.53%. BridgeBio Pharma's return on equity of 0.00% beat Indivior's return on equity.
Indivior has higher revenue and earnings than BridgeBio Pharma. Indivior is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.
60.3% of Indivior shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 24.7% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, BridgeBio Pharma had 3 more articles in the media than Indivior. MarketBeat recorded 8 mentions for BridgeBio Pharma and 5 mentions for Indivior. Indivior's average media sentiment score of 1.16 beat BridgeBio Pharma's score of 0.46 indicating that Indivior is being referred to more favorably in the media.
Indivior has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500. Comparatively, BridgeBio Pharma has a beta of 1.05, meaning that its stock price is 5% more volatile than the S&P 500.
Summary
BridgeBio Pharma beats Indivior on 10 of the 18 factors compared between the two stocks.
Get Indivior News Delivered to You Automatically
Sign up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Indivior Competitors List
Related Companies and Tools
This page (NASDAQ:INDV) was last updated on 1/21/2025 by MarketBeat.com Staff
Free INDV Stock Alerts